Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Roll-over Study Evaluating the Long-term Safety and Efficacy of an Oral Dose of Verducatib q.d. in Patients With Bronchiectasis (AIRTIVITY®-ON)

NCT07915219 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07915219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Roll-over Study Evaluating the Long-term Safety and Efficacy of an Oral Dose of Verducatib q.d. in Patients With Bronchiectasis (AIRTIVITY®-ON)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Not yet recruiting
Start date
January 11, 2027
Completion date
September 10, 2029
Enrollment
1,500 (estimated)
Sites
394

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 1 arm.

  • Participants with bronchiectasis rolling over from parent trials Experimentalverducatib

    Participants with bronchiectasis who completed parent trials AIRTIVITY® (1397-0014) or CLAIRLEAF® (1397-0017) and did not prematurely discontinue the trial drug.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Occurrence of treatment-emergent adverse events (TEAEs) over the course of this trial up to 78 weeks

Lead sponsor's other trials

Boehringer Ingelheim, most recent start first.

Similar trials

Same condition (Bronchiectasis) and phase, most recent start first.